Study Validating Esophageal Cancer Test Accepted by Gastroenterology Journal
The mass spectrometry-based assay achieved 100% sensitivity in detecting patients who later progressed to cancer in a blinded cohort study.
Category: Cancer
Cancer
Latest
Cancer
Latest
Circulogene Launches Tissue-Based Genomic Profiling Assay for Solid Tumors
OncoGenDx analyzes 335 DNA genes and 72 RNA genes using next-generation sequencing technology to support treatment decisions.
Cancer
Latest
Quest Diagnostics to Expand Blood-Based Colorectal Cancer Screening Access
The company is collaborating with Guardant Health to make Guardant's Shield test available through Quest's nationwide network of provider clients and patient service centers.
FDA OKs Cartridge-Based Companion Diagnostic Test for Colorectal Cancer
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
Read More
Circulating Tumor DNA Shows Promise for Guiding Immunotherapy in Lung Cancer
Study of 177 patients with limited-stage small cell lung cancer demonstrates ctDNA’s potential to personalize consolidation immunotherapy decisions.
Read More
Genomic Test Shows Promise for Guiding Chemotherapy Decisions in Metastatic Prostate Cancer
Phase 3 STAMPEDE trial data demonstrates Decipher Prostate test can predict docetaxel treatment benefit, potentially helping patients avoid unnecessary toxicity.
Read More
Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read More
Cerebrospinal Fluid Test Identifies Brain Cancers with 100% Specificity
Johns Hopkins researchers develop multi-analyte assay combining tumor DNA, mutations, and immune cell signatures for central nervous system cancer diagnosis.
Read More
FDA Grants De Novo Authorization for AI-Powered Prostate Cancer Prognostic Software
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read More
VieCure Adds Summit Cancer Centers to Community Oncology Network
Multi-disciplinary cancer center will implement Halo Intelligence platform to enhance precision oncology capabilities across Pacific Northwest.
Read More
Ultrasensitive MRD Test Shows Greater Prognostic Accuracy Than PET/CT in Lymphoma
Pooled analysis of 137 patients shows the assay achieved 86% sensitivity and 91% specificity for relapse detection in large B-cell lymphoma, leading to NCCN guideline inclusion.
Read More
Blood Test Achieves 85% Accuracy in Predicting Breast Cancer Immunotherapy Response
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
Read More
Mass General Brigham Launches Trials of Blood Test to Guide Post-Surgery Cancer Care
Two studies will evaluate circulating tumor DNA as a guide for post-surgical cancer treatment decisions.
Read More
Colorectal Cancer Screening Surges 62% Among Adults 45-49, Driving Early-Stage Diagnoses
Two new American Cancer Society studies reveal significant increases in colorectal cancer...
Read More
Three Boston Institutions Launch Precision Genomics Initiative for Pediatric Cancer Testing
Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs form BrightSeq collaborative to develop novel clinical diagnostic assays for rare pediatric cancers.
Read More
At-Home Cervical Cancer Screening Now Available, Starting in California
This marks the first time a US Food and Drug Adminstration-authorized self-collection device is available for at-home cervical cancer screening in the US.
Read More
Test Gains Medicare Coverage for Early-Stage Breast Cancer Recurrence Monitoring
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
Read More
CyPath Lung Flags Early-Stage Cancer Overlooked by Previous Tests
A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- ...
- 186